Skip to content

Earnings call

Aurobindo Pharma Q1 FY26 earnings call: Aurobindo Pharma is confident of achieving its internal target margin of 20%-21% range in FY26

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company is confident of achieving its internal target margin of 20%-21% range in FY26. The company invested approximately $145 million in its China facility, which commenced production from Q4 FY25 and started invoicing in Q1 FY26. Consolidated revenues grew by 4% year-on-year to ₹ 7,868 crores in the first quarter ended June 30, 2025. The company generated a net cash inflow of $98 million during the first quarter ended June 30, 2025, improving its net cash position, including investments, to $140 million as of June 30, 2025, from $42 million as of March 31, 2025; it had a net cash position of $140 million as of June’25.

The numbers management gave

Results

  • Consolidated revenues grew by 4% year-on-year to ₹ 7,868 crores in the first quarter ended June 30, 2025.
    Show source
    • Our consolidated revenues grew by 4% year-on-year to ₹ 7,868 crores, reflecting a steady start to FY26.
  • U.S. formulation base business remained stable in the first quarter ended June 30, 2025.
    Show source
    Our U .S. formulation base business remained stable and resilient.
  • EBITDA was ₹ 1,603 crores with a margin of 20.4% in the first quarter ended June 30, 2025.
    Show source
    • EBITDA for the quarter was ₹ 1,603 crores with a margin of 20.4 %.
  • EBITDA contribution from gRevlimid in Q1 FY26 was about ₹ 150 crores lower than in Q1 FY25 and ₹550 crores lower than in Q4 FY25.
    Show source
    Q1 FY26 was lower by about ₹ 150 crores versus Q1 FY25 and ₹550 crores versus Q4 FY25.
  • EBITDA excluding Revlimid grew 12% year-on-year in Q1 FY26.
    Show source
    Ex-Revlimid growth in EBITDA is 12% year-on-year.
  • ARV Formulation revenue increased 55% year-on-year to ₹355 crores or $41 million in the first quarter ended June 30, 2025, driven primarily by volume uptick and new tender wins in several geographies, which it expects to sustain in the near term.
    Show source
    ARV Formulation: ARV revenue delivered a strong 55% year-on-year increase, reaching ₹355 crores or $41 million.
Show 16 more statements

Results

  • Gross margin was 58.8% in the first quarter ended June 30, 2025, compared to 59.4% in Q1, supported by softer raw material prices and better product and business mix.
    Show source
    Operational and Financial Highlights: Gross margins remained stable for the quarter at 58.8% compared to 59.4% in Q1 supported by softer raw material prices and better product and business mix.
  • Contribution amounted to ₹4,629 crores in the first quarter ended June 30, 2025.
    Show source
    Our contribution amounted to ₹4,629 crores.
  • R&D expenditure was ₹367 crores, representing 4.7% of revenue, in the first quarter ended June 30, 2025.
    Show source
    R&D expenditure was ₹367 crores, representing 4.7% of the revenue.
  • Net CapEx was $73 million in the first quarter ended June 30, 2025, aligned with its investment priorities in expanding manufacturing footprint, enhancing compliance and automation.
    Show source
    Net CapEx for the quarter stood at $73 million, aligned with our investment priorities in expanding manufacturing footprint, enhancing compliance and automation.
  • Finance costs declined to 4.9% in the first quarter ended June 30, 2025, from 5.5% in the previous quarter, benefiting from prudent treasury management.
    Show source
    3 Aurobindo Pharma Limited 05 August 2025 Our Finance costs declined to 4.9% from 5.5% in the previous quarter, benefiting from prudent treasury management.
  • PAT was ₹824 crores in the first quarter ended June 30, 2025.
    Show source
    PAT for the quarter was ₹824 crores.
  • Overall CapEx is around $73 million in the first quarter ended June 30, 2025, including the new market, PLI and everything put together, compared to an earlier trend of around more than $100 million.
    Show source
    Like this quarter, the overall CapEx is around $73 million, including the new market, PLI; everything put together compared to earlier trend of around more than $100 million.
  • European business margins have moved from the mid-teens a few quarters ago to the high teens and are expected to touch the 20 mark very soon.
    Show source
    But as far as the margins are concerned, where you would have known several, a few quarters ago where we were in the mid-teens, but now we are going strongly much above to the high teens and touching the 20 mark very soon.
  • PEN-G unit is currently operating at around 50 to 60%.
    Show source
    S. Subramanian: PEN-G unit currently, we are doing around 50 to 60%.
  • Lannett's current EBITDA margin run rate is around 15% on a trailing 12-month basis, which Swami Iyer described as a conservative estimate.
    Show source
    I mean, at this point of time, if I take the TTM trailing 12 months, if I take any period, we are somewhere around that and I believe that's a very conservative estimate.
  • Consolidated revenues grew primarily due to continued momentum in European and growth market operations, along with incremental contributions from its ARV segment.
    Show source
    This growth was driven primarily by continued momentum in our European and growth market operations, along with incremental contributions from our ARV segment.
  • Reduced working capital is helping its free cashflow.
    Show source
    In terms of the free cashflow, I mean, we have reduced the working capital considerably and that is what's helping.
  • Working capital improvement and reduction in CapEx are contributing to its free cashflow.
    Show source
    So, there is a working capital improvement taking place and there is a reduction in the CapEx.

Money and capital

  • The company generated a net cash inflow of $98 million during the first quarter ended June 30, 2025, improving its net cash position, including investments, to $140 million as of June 30, 2025, from $42 million as of March 31, 2025; it had a net cash position of $140 million as of June’25.
    Show source
    The company has a net cash position of $140 million as of June’25.
  • Gross debt reduced to $884 million from $930 million at the end of March’25, reflecting ongoing deleveraging and disciplined capital allocation.
    Show source
    Gross Debt reduced to $884 million, down from $930 million at the end of March’25, reflecting ongoing deleveraging and disciplined capital allocation.
  • The company had a net cash position of $140 million as of June’25. Replaced by a later filing.

What it expects ahead

What management expects

  • The company is confident of achieving its internal target margin of 20%-21% range in FY26.
    Show source
    We are confident of achieving our internal target margin of 20%-21% range in FY26.
  • The company will strive to achieve cash generation of $100 million quarter on quarter, subject to any strategic expenditure being incurred.
    Show source
    We will strive, we will endeavour to achieve a cash generation of $100 million quarter on quarter, I mean, subject to any strategic expenditure being incurred.
  • Swami Iyer believes Lannett will be able to achieve an EBITDA margin of 15% or more in the future.
    Show source
    We think that in the future, we will be able to get a margin of 15% or more.
  • The company expects revenue from its Biosimilars business to start from Q3-Q4 with well above the company average EBITDA margins, as approvals have started coming in from EU.
    Show source
    We expect revenue to start from Q3-Q4 with well above the company average EBITDA margins.
  • The company expects volume expansion, continued product launches and a stable pricing environment, especially in the U.S. and Europe, to support growth; ramping up commercial operations at new manufacturing sites would further support topline growth and margin improvement in the upcoming quarters.
    Show source
    Our confidence is supported by expected volume expansion, continued product launches and a stable pricing environment, especially in the U.S. and Europe.
  • The company is trying to improve yields at its PEN-G unit to cut down losses; after stabilizing it in the next two months, the company will scale it up.
    Show source
    And once we stabilize that in the next two months, we will scale it up.
Show 1 more statement

What management expects

  • Recent strategic U.S. acquisition will help it continue growth momentum in the medium term. Replaced by a later filing.
    Show source
    4 Aurobindo Pharma Limited 05 August 2025 Lastly, our recent strategic U.S. acquisition will help us to continue the growth momentum in the medium term.

What it is building and selling

Projects and capacity

  • The company invested approximately $145 million in its China facility, which commenced production from Q4 FY25 and started invoicing in Q1 FY26.
    Show source
    Approximately $145 million invested in China facility, which has commenced production from Q4 FY25 and invoicing started in Q1 FY26.
  • China facility has an initial capacity of 2 billion units +, is ramping up as expected, will begin contributing to revenue in the coming quarters and is expected to break even at EBITDA level by Q3 FY26.
    Show source
    This facility with an initial capacity of 2 billion units + is ramping up as expected and will begin contributing to revenue in the coming quarters and expected to break even at EBITDA level by Q3 FY26.
  • The company invested approximately $70 million in two U.S. facilities, Dayton, which will start producing from Q2-Q3 FY26, subject to approval from the regulatory authorities.
    Show source
    Approximately $70 million in two U.S. facilities, Dayton, will start producing from Q2-Q3 FY26.
  • The company spent approximately $30 million in Biologics CMO, with balance $100 million plus expected to be invested between now and March’27.
    Show source
    Approximately $30 million spent in Biologics CMO, balance $100 million plus expected to be invested between now and March’27.
  • TheraNym initially started its project with two 15-kL mammalian cell culture bioreactor lines, with CapEx guidance around ₹1,000 crores to complete and fully commission the project.
    Show source
    TheraNym, as you know, we initially started the project with two 15-kL mammalian cell culture bioreactor lines and the CapEx guidance was around ₹1,000 crores to complete the project and fully commission it.
  • TheraNym's project requires adding two more 15-kL bioreactor manufacturing lines and associated purification and utility capacities; the lines will come into full operation somewhere in 2028.
    Show source
    This means that or this translates into addition of the need to add two more 15-kL bioreactor manufacturing lines and it’s associated purification and utility capacities.
Show 7 more statements

Projects and capacity

  • TheraNym's additional CapEx guidance is around ₹350-₹400 crores to enhance capacities and strengthen the collaboration with MSD.
    Show source
    So, the additional CapEx guidance that we provided of around ₹350-₹400 crores essentially is to enhance capacities and strengthen our collaboration with MSD.
  • The company is not expecting any further greenfield CapEx investments in the near to mid-term and will focus on maintenance and replacement CapEx and capacity enhancements in existing facilities.
    Show source
    To reiterate, the company is not expecting any further greenfield CapEx investments in the near to mid-term.
  • The company has taken a decision to add two more oncology lines to meet European requirements, as demand is outstripping capacity.
    Show source
    So in fact, we have taken a decision to add two more lines, oncology lines to take care of the European requirements.

Demand and pricing

  • Lannett has consistently been able to get and utilize a quota, and market pricing is pretty stable.
    Show source
    They have been consistently able to get a quota, they have been consistently able to utilize a quota, which is very important, and the market pricing is pretty stable.

Segments

  • Lannett has manufacturing capability for oral solids, liquids and potent substances.
    Show source
    They also have manufacturing capability for oral solids, liquids and potent substances.
  • The company is steadily moving European products in-house as much as possible, while small volumes or technologies it cannot handle continue to come from third-party suppliers.
    Show source
    And coming to the third party 10 Aurobindo Pharma Limited 05 August 2025 sourcing versus in-house, we are steadily moving the products in-house as much as possible.

Deals and partners

  • The company is working towards strengthening its collaboration with MSD in the CMO space. Replaced by a later filing.
    Show source
    In the CMO space, what we are trying to do is that we are working towards strengthening our collaboration with MSD.

Risks, rules and outside factors

Rules and policy

  • The company secured renewal of consent to operate and wastewater disposal clearance from the Andhra Pradesh Pollution Control Board for its P en-G manufacturing plant.
    Show source
    • In another major development, we are pleased to share that we have secured the renewal of consent to operate as well as the wastewater disposal clearance from the Andhra Pradesh Pollution Control Board for our P en-G manufacturing plant.

Everything else said on the call

Group structure

  • The company has given 9 months as a matter of abundant caution for the Lannett acquisition to close, though it could be earlier, and will do what it can to expedite it; if clearance comes earlier, integration would happen earlier.
    Show source
    We have given 9 months as a matter of abundant caution, it could be earlier.
  • Lannett's manufacturing capacity is not fully utilized; it utilizes only around 40%, leaving around 60% unused.
    Show source
    The manufacturing capacity is not fully utilized, they utilize only to the extent of ballpark around 40%, which gives us around 60%.
  • Lannett has a CMO business with a few countries with approval in some other markets, which Aurobindo Pharma thinks it can tap better because it has good presence in those markets.
    Show source
    And another factor is that they have a good CMO business with a few countries with approval in some of the other markets, which we think we will be able to tap better because we have got good presence in those markets.
  • Some products manufactured at Lannett could have good potential in one of Aurobindo Pharma's neighbouring countries and beyond, because Lannett has the regulatory approach for those countries.
    Show source
    And we are understanding is that some of the products that is being manufactured there at Lannett could have a good potential in one of our neighbouring countries and also we can spread out a little beyond that because they do have the regulatory approach for those countries.
  • The company believes it can quickly leverage its large portfolio to bring more products in demand in the U.S., especially for the government market, to Lannett, which could be an immediate gainer.
    Show source
    Aurobindo has a large portfolio, we can quickly leverage our large portfolio to bring in some more products, which are in demand in the U.S., especially for the government market and that could be an immediate gainer.
  • Lannett acquisition is subject to FTC approval. Replaced by a later filing.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Damayanti Kerai: Hi. Good Morning, everyone. This is Damayanti from HSBC Securities. Sir, my first question is on gRevlimid. So, just to clarify, this ₹150 crores less number and then ₹550 crores less number versus Q4 is at the EBITDA level, right?

    Answer, s subramanian

    S. Subramanian: You can take that is at the topline level. EBITDA you can work it out yourself, you must be knowing, I am sure.

  2. Question

    Damayanti Kerai: Okay, so this is at the revenue level, okay. That was good. My question is, on gRevlimid definitely pricing pressure has intensified and some of your peers have also mentioned this. So, from an opportunity perspective, do you think you can still make some reasonable sales from this product in FY26 or this is an opportunity which is broadly gone now?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yeah. Damayanti, in fact, I think we mentioned this in the last call as well. Most of our Revlimid settlement quantities, we have sold it. We have nothing more to sell other than a minimal this thing [remaining quantity]. So, the price impact will not have any bearing on our future revenues. But at the same time, we don't expect significant sales coming from gRevlimid because we already sold off.

  3. Question

    Damayanti Kerai: Okay. My second question is, Sir, if you can explain what has happened in the API and do you think it's a temporary phenomenon and you can see recovery ahead?

    Answer, s subramanian

    S. Subramanian: API, the turnover has dropped because of the mainly because of the pricing pressures. Otherwise, I think over a period of time it will start recovering because it cannot sustain for a long time, right. That is the main reason. 5 Aurobindo Pharma Limited 05 August 2025 Damayanti Kerai: Okay.

  4. Question

    Tushar Manudhane: Yeah, thanks for the opportunity. Sir, with respect to the, let's say, operational losses for various plants, if I have to club together for FY26, if you can share that number? And subsequently, how to think about that number for FY27, considering any new plant that might come up in FY27?

    Answer, s subramanian

    S. Subramanian: See, last year, we have incurred losses predominantly, as you know, in Pen- G, Qule and other things, right. And as I explained in the script itself, I said, we are expecting good EBITDA starting Q3 onwards. So, the losses will come down. So, that's the main thing. Out of the total, Pen-G was the biggest loss last year and hopefully that will not get continued.

  5. Question

    Tushar Manudhane: So, this year how much that number for this like first two quarters given that the scale up probably will have benefits coming from second half?

    Answer, s subramanian

    S. Subramanian: See, last quarter was a very low number, around less than ₹50 crores. But one good thing is we started the production, we had a good production in, I mean, even though the plant has really the first output came sometime in the second fortnight of July, we had a good ramp up. And what is very encouraging is the yields are improving day by day and hopefully it will get stabilized in the month of August and September. So, that is the reason we think by Q3 onwards we’ll be able to do well. That's the main reason.

  6. Question

    Tushar Manudhane: And, Sir, just to add to that, like how much PLI income to consider for this year?

    Answer, s subramanian

    S. Subramanian: I think we will be expecting anywhere between 7,000-8,000 tonnes production. That means at least we can take more than half of it, maybe around ₹150 crores. I mean, but the clear numbers, etc, will be known in the next quarter because the key thing is we need to sustain these yield improvements, which has happened in the last 3-4 days in this month of August and September. Then that will give you a very clear indication in the next quarter.

  7. Question

    Tushar Manudhane: Understood, Sir. And just one more from my side. So, maybe the basis contract the gRevlimid business is no more. So, any which case increased competition and all, so beyond contract will we be able to sell or it's like because of the contract we will not sell itself and so the other guys have their share and subsequently the pricing still remains steady. How to think about gRevlimid as a product? 6 Aurobindo Pharma Limited 05 August 2025 Yugandhar Puvvala: So, Tushar, in general, the entire market will open up from 1st February, 2026.

    Answer, yugandhar puvvala

    And we are getting prepared to take more market shares starting from February’2026. So, even though like we will have limited sales of gRevlimid for next 1-2 quarters, but we expect Q4 because the entire market will open up and we have capacities to take the market share. So, it will be an open market game at that point of time.

  8. Question

    Tarang Agarwal: Okay. Because a 16% decline is something, to the best of my knowledge, I've never seen in this business in the last multiple quarters.

    Answer, s subramanian

    S. Subramanian: Well, it may be a 16% on the topline, it may not be that much percentage in terms of the volume. Plus, you know, this quarter is always a summer quarter, so the offtake is also very low across India.

  9. Question

    Tarang Agarwal: Got it, okay. Second question is on Eugia. I mean, if you could give us the U.S. sales numbers of Eugia for Q4 and Q1; Q4 of FY25 and Q1 of FY26.

    Answer, s subramanian

    S. Subramanian: So, we are not giving that number separately, Tarang. Yugandhar Puvvala: But in general, Tarang, we already mentioned that the regular injectable sales is growing and we have shown a growth of 11%.

  10. Question

    Tarang Agarwal: This 11% is on a year-on-year basis, correct?

    Answer, s subramanian

    S. Subramanian: Quarter-on-quarter. Yugandhar Puvvala: It is year-on-year as well as quarter -on-quarter, it is almost similar number.

Show 22 more questions
  1. Question

    The third question is on TheraNym. Doctor, just wanted to check, I mean, I think the initial estimate of capacity creation was about ₹1,000 crores, which was later appended to about ₹1,500 crores. I think Subbu Sir did call out in his opening comments of some outlay already being done, if you could just rehash in terms of what's happening there and in terms of are you seeing incremental demand in that business? Dr. Satakarni Makkapati: Good morning, Tarang.

    Answer, satakarni makkapati

    TheraNym, as you know, we initially started the project with two 15-kL mammalian cell culture bioreactor lines and the CapEx guidance was around ₹1,000 crores to complete the project and fully commission it. In the CMO space, what we are trying to do is that we are working towards strengthening our collaboration with MSD. This means that or this translates into addition of the need to add two more 15-kL bioreactor manufacturing lines and it’s associated purification and utility capacities. These lines will also come into full operation somewhere in 2028. So, the additional CapEx guidance that we provided of around ₹350-₹400 crores essentially is to enhance capacities and strengthen our collaboration with MSD. If that answers your question, Tarang.

  2. Question

    Tarang Agarwal: It does, it does. That's quite helpful. Sir, just a couple of more. One, on the free cash generation, last two quarters consistently almost about $100 million of free cash generation for the business on each quarter basis. Is that the trend that we should work with or some working capital expansion should probably...I mean , the place where I'm trying to get at is the business now at a point of time where $400 -$450 million of regular free cash generation is something that's visible for you? That's one. And second on Lannett, if you could just walk us through the transaction and why it would take about 8 -12 months for the transaction to achieve closure? Thanks. Those two fro

    Answer, s subramanian

    S. Subramanian: Yeah, I'll answer the first one and Swami will answer the second one. In terms of the free cashflow, I mean, we have reduced the working capital considerably and that is what's helping. Apart from that, overall CapEx has come down in the last two quarters. Like this quarter, the overall CapEx is around $73 million, including the new market, PLI; everything put together compared to earlier trend of around more than $100 million. So, that is also helping. So, there is a working capital improvement taking place and there is a reduction in the CapEx. That is the reason why it is there.

    Answer, s subramanian

    We will strive, we will endeavour to achieve a cash generation of $100 million quarter on quarter, I mean, subject to any strategic expenditure being incurred.

  3. Question

    Tarang Agarwal: Sure.

    Answer, swami iyer

    Swami Iyer: Okay. So, on the Lannett acquisition, this is subject to FTC approval. Obviously, there will be a lot of back and forth. We have given 9 months as a matter of abundant caution, it could be earlier. But, obviously, we will do whatever we can to expedite this. If it gets clearance earlier, obviously the integration would happen earlier.

  4. Question

    Tarang Agarwal: Sir, just wanted to understand, I mean, how difficult or how soon can you integrate this business? What are the synergies that you're looking between both the setup and some metrics on the broader market in which the target is operating? 8 Aurobindo Pharma Limited 05 August 2025 Swami Iyer: Sure.

    Answer, swami iyer

    So, we believe that integration is very easy because we have similar kind of products, only they are in ADHD segment. They are mostly into controlled substances and even the other product that they have, We believe that those are very close to what we have. What they have, one other advantage is they had a strong BD team, which we have started working on now, and they also have a bit of in-licensing. That is going to be clearly one synergy. The other synergy, they have got 70 plus active products and many of them are in controlled substances. They're all in niche area where the products are in short supply. We believe, based on what we have seen quarter on quarter trend, that there could be good potential for an upside in this business.

    Answer, swami iyer

    They have been consistently able to get a quota, they have been consistently able to utilize a quota, which is very important, and the market pricing is pretty stable. We also think there are some synergies in terms of rationalization of some of the resources that would immediately, some of these could be low-hanging fruit. And another factor is that they have a good CMO business with a few countries with approval in some of the other markets, which we think we will be able to tap better because we have got good presence in those markets. And we are understanding is that some of the products that is being manufactured there at Lannett could have a good potential in one of our neighbouring countries and also we can spread out a little beyond that because they do have the regulatory approach for those countries. They also have manufacturing capability for oral solids, liquids and potent substances. The manufacturing capacity is not fully utilized, they utilize only to the extent of ballpark around 40%, which gives us around 60%. Aurobindo has a large portfolio, we can quickly leverage our large portfolio to bring in some more products, which are in demand in the U.S., especially for the government market and that could be an immediate gainer.

    Answer, swami iyer

    Lannett has also discontinued some of the products. We think there is scope for, with our procurement practices, with our ability, we believe that we can revive those products, especially for the government markets. Last but not the least, they have a very good workforce in the manufacturing. They all have a very long tenure and the wage level, everything is very comparable or better. So, that gives us a good feel about the whole acquisition. Net-net, we are very upbeat about this.

  5. Question

    Thanks for the opportunity, Sir. My first question on the U.S. business, you have commented about destocking impact, what is the nature of this destocking, Sir? Is it anything relating to tariff -related preparation or can you clarify this?

    Answer, swami iyer

    Swami Iyer: Yeah, Surya, what Subbu had alluded to was primarily, the tariffs were supposed to go into effect from April 1. If you see, there was a huge surge, much more than the normal quarter surge in the quarter ending March. We believe that some of the wholesalers have stocked up the product in anticipation. They were also asking us to keep more inventory and they themselves seemed to have stocked up. We have not seen a decline in the demand of the oral solids in the U .S. nor have we seen any loss of awards, any major award. So, it is our understanding that this is primarily because the wholesalers have stocked up during the last quarter and they are winding down those positions.

  6. Question

    Surya Patra: Okay. So, it is a quarter -specific issue then, I believe.

    Answer, swami iyer

    Swami Iyer: Yes, not just that. For Q1, this has been a fairly good quarter, especially on the total volume that has been sold from the wholesalers. Typically, Q1 is a non -seasonal quarter but it has been a fairly decent quarter, I would say.

  7. Question

    Surya Patra: Sure, Sir. My second point is about the Pen-G plant, Sir. So, now having resumed our operation there, what is the kind of visibility that we are having in terms of the ramp -up? And also, in the previous quarter that we had indicated about the MIP, the Minimum Import Price, so what is the update on that front, whether that is a kind of necessity given the current situation? And what is your risk assessment about that relating to the Pen-G, if you can?

    Answer, s subramanian

    S. Subramanian: So, in terms of the Pen-G production, as I said, the production is improving in the last 3-4 days and the yields are improving. We believe, I mean, we are pretty confident this going will be very good in the coming 2 months and we will be able to do very well in the Q3, that is what we believe. And in terms of the MIP, I am not sure we can talk about it in detail because there are lot of things that are happening. So, probably we may be able to talk about it in the next call.

  8. Question

    Surya Patra: Okay, Sir. My last question is about the European business. Sir, obviously that we have been seeing very strong performance consistently since last few quarters and you have already guided about a kind of strong growth in the FY26. So, my point was about the margin performance there. Sir, with the new capacity addition, what is the kind of outsourcing that we are dependent on external resources for European operation now? And what it is likely to improve to by the end of this year? And hence what margin performance one should anticipate for the European markets.

    Answer, v muralidharan

    V. Muralidharan: Yeah, from the market perspective I can handle this, then on the plant related, Subbu, I would suggest you to do that. Surya, first of all pleasure speaking to you, good morning and thank you for your compliments for the European business. Yes, we have been demonstrating the sustained momentum since last several quarters and happy to be also posting a strong number this quarter. And coming to the third party 10 Aurobindo Pharma Limited 05 August 2025 sourcing versus in-house, we are steadily moving the products in-house as much as possible. Of course, there are certain small volumes or some technologies which we cannot handle, so this continue to come from the third party suppliers. But as far as the margins are concerned, where you would have known several, a few quarters ago where we were in the mid-teens, but now we are going strongly much above to the high teens and touching the 20 mark very soon. So this is on the margin perspective.

    Answer, s subramanian

    S. Subramanian: Yeah, so in terms of the production, I'm sure you must be knowing, we have been having a capacity around three to four billion tablets now, as explained in the last or previous call. We have ramped up the capacity further and that has helped in terms of supplying more material and that is also one of the reasons the European team was able to take the sales to greater heights, right? And we will continue to do that and in terms of the margin also, because of the in-house production and we were able to increase the margin percentage also. And your last question was in terms of percentage, we were somewhere around 50-50 or slightly above in favor of the captive consumption.

  9. Question

    Surya Patra: Okay, so just whether the injectables have seen any ramp up in Europe?

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Yes, in fact, we have been growing at a rate of 20 percent for European market because we find a lot of shortages happening in Europe and Murali's team could take full advantage of the market situation there. So now like what's happening is, our capacity versus demand, the demand is outstripping the capacity. So in fact, we have taken a decision to add two more lines, oncology lines to take care of the European requirements. I'm quite positive that Europe has continued to grow.

  10. Question

    Neha Manpuria: Yeah, thanks for taking my question. You know, two questions on the U.S. business. Swami Sir, if I look at the oral solid business, could you quantify how much would be this de-stocking impact just to understand, you know, how the business is done both from a year-on-year and a quarter-on-quarter perspective?

    Answer, swami iyer

    Swami Iyer: You know, it's hard to quantify exactly that kind of amount but what I'm saying is, in terms of total demand for the U.S., it has been pretty stable and we have got our awards intact barring few losses and few gains. So overall, I think we are in good shape there. I am not exactly sure on how much. My guess would be, it could be anywhere between half a month to one month. That's my guess because if the wholesalers have stocked it, they would have stocked it for at least 15 days to one month for the tariffs. That's only my guess. I can't say precisely.

  11. Question

    Neha Manpuria: Understood. And then I'm just wondering about the, you know, U.S. business decline quarter -on-quarter and, you know, Yugandhar Sir’s comment that the injectable business seems to be improving. If it's just 15 days of, you know, 15 days or one month of de-stocking, you know, the entire, you know, 550 crores decline quarter-on- 11 Aurobindo Pharma Limited 05 August 2025 quarter is just Revlimid? I mean, if I were to look at the last quarter injectable base or Eugia base that we used to mention, it seems like the ex-Revlimid business isn't actually showing as much improvement or, you know, normalcy as, you know, what we seem to be leading. So what am I missing here in the U.S. b

    Answer, s subramanian

    S. Subramanian: Neha, you cannot do that. No, U.S. business is not only the solid orals and injectables. We have the branded injectable. We have the OTC from direct dispatches from India, which is a significant amount. So it's a combination of everything. So if you say if you deduct it and then is it because of the oral, etc., it is not like that. It's a combination of many things.

  12. Question

    Neha Manpuria: No, sir. What I'm trying to understand is that, you know, how far are we from the injectable business getting back to, you know, the pre -disruption levels? You know, is it 20 percent lower, 30 percent lower? That's what I'm trying to understand.

    Answer, yugandhar puvvala

    Yugandhar Puvvala: Let me just clarify a few things. Yes, the G-Revlimid was much higher in Q4. Your assumption is to some extent right. Second thing is we are back to pre -disruption levels with respect to injectable business. I'm very, very confident. My entire injectable business is growing and all the production facilities are back and running and Eugia 3 is back. So we are very, very confident that we have come back to the pre -disruption levels.

  13. Question

    Neha Manpuria: Understood. And my last question is on Lanett. Lannett also had a very good portfolio that they were planning to file. I think you also alluded in your presentation in Lannett that, you know, there are some NCE minus 1 opportunities. Are these opportunities still valid, you know, once we finish integration, you know, the acquisition of Lannett? And also will there, do you think, given the portfolio overlap based on IQVIA data that we have with Lannett, there would be direct means that could be required to get FTC approval in your view?

    Answer, swami iyer

    Swami Iyer: First things first, on the pipeline, we not only get the products in commercial stage, we also get the products in pipeline. There are some good pipeline products. That's what I would like to say. At this point of time, we are quite excited about what they have in pipeline, at least a few products. Now, as far as the FTC is concerned, FTC has to review this, the sheer volume of work that they have to do, because I've been there, you know, it's a big company, we have to submit all the data about all the products and they would take time reviewing it. So, it could take time, but we feel optimistic that we should be getting it and getting for the entire portfolio of comm ercial products in the pipeline, barring few where there could be conflicts. So overall, we, like I said before, we are quite upbeat on what we will, what we are likely to get here.

  14. Question

    Bino: Hi. Good morning and good evening. First question, Subbu Sir, our gross margin is holding up at about 59%. You mentioned that Revlimid was down Q-O-Q by about, I think $17 million and there was pricing pressure in the APIs as well. So, what's helping us hold up the gross margin at 59%, which is comparable QOQ? 12 Aurobindo Pharma Limited 05 August 2025 S. Subramanian: As explained in the original script itself, no, it is a combination of multiple things.

    Answer, s subramanian

    There is a positive favourable mix in terms of the businesses when, for example, when the API business percentage of revenue share goes down, automatically, it increases the weighted average because the API does not give the margin same as the company average margin like that and we also had good, Eugia done well, plus we also, the existing product profile also good in the solid orals. So it's a combination of multiple t hings, Bino.

  15. Question

    Bino: Okay. And second, what are the Pen-G prices in the market today? And what is your latest estimate about your profitability levels? At what price you would be profitable?

    Answer, s subramanian

    S. Subramanian: I think the current market price is anywhere north of $20 [per kg]. We'll be profitable somewhere around, I mean, we'll be breakeven somewhere around maybe a couple of dollars plus or minus like that, depending upon the yield in that particular month or the quarter . Bino: Okay, understood. And last one question, for being eligible to get the PLI payment, is there a minimum level of production that we need to have in a year?

    Answer, s subramanian

    S. Subramanian: No, there is no minimum level of production. Whatever you produce, you will get a percentage on that, you will get the PLI incentive. Bino: Understood! Thank you very much. I'll join back in the queue.

  16. Question

    Shyam Srinivasan: Yeah, good morning. Thank you for taking my question. Just the first one on the biosimilar launches in Europe, Dr. Satakarni, if you could just highlight what are the things that we need to keep in mind? I think the presentation talks about Q3, Q4. So the kind of infrastructure, the kind of preparation, maybe initial market shares that we are targeting. So if you could help us outlay the commercial strategy. Dr. Satakarni Makkapati: Shyam, so to answer your question, we started making the manufacturing quantities for commercial supplies.

    Answer, satakarni makkapati

    In fact, we made one supply as well to meet the requirement in the UK market. So the first six months leading up to March would essentially be meeting the l aunch quantities, enabling our commercial operations teams and our partners to park the launch quantities in the markets they desire to. So I don't have a number guidance for the first six months. It will be a very small sin gle digit commercial revenues trickling in. The focus for us right now is to ensure that we have adequate supplies, the supply chain is sorted out. Our QP testing services that we are stabilizing in Europe through CRO partners and through our own setup in Malta, they function seamlessly in releasing and testing biosimilars, which is required in Europe. You need a qualified personnel [QP] testing.

    Answer, satakarni makkapati

    So all this will take about a couple of quarters to stabilize. As you know that we have four product approvals that we received from Europe, three with the European medicine agency and Bevqolva (tratsuzumab) with MHRA. So all 4 products, we are ready to supply these products into the European market. I hope to stabilize 13 Aurobindo Pharma Limited 05 August 2025 everything from supply chain to closing out on a couple of distribution deals that I am focusing on in Europe right now in the markets that we are not directly present. So in the markets that Aurobindo is directly present, Aurobindo will handle the commercialization of these products. In the markets that we are not strong in, we have a few partners. For example, in Nordics, we have Orion Pharma.

    Answer, satakarni makkapati

    In some other markets, I cannot disclose their names, but we are working on closing a few deals. So I see by the April quarter next, we would have fairly stabilized our commercial supplies and we will have some plans laid out for how much we will be able to sell in these markets for the year. Shyam, that answers your question.

  17. Question

    Shyam Srinivasan: Yeah. Thank you, Dr. Satakarni. Just if you could give us, like your credit for the first European launch at your earlier shop. So you know, in the last whatever, you know, five, six, maybe even a decade of doing this, what are some of the big differences you see? Is profitability in Europe for biosimilars distinctly different now and lower perhaps? So, if you could comment on profitability as well. Dr. Satakarni Makkapati: It is a very subjective question.

    Answer, satakarni makkapati

    I have been asked this question on multiple occasions. From my first launch in Europe way back, the India's first launch in Europe way back in 2012 to now, absolutely, there is a big difference in the pricing erosion that we are witnessing, which affects the profitability margins. But what needs to be also understood is that the European landscape is extremely distinct in a manner that, there are few countries which are extremely tender-driven or solely tender-driven, if I may use that word. And there are a few countries where the retail prices are still very exciting, where you can still make a good 85, 80% gross margins. And there will be countries where you will make probably around 15 to 20%. So you need to look at Europe as a whole and see if a company is putting out a product at a COGS and a transfer price to its partners, where it can still make an overall margin of, say, 40 to 60%, then I believe that they are still in the game. But having said that, in the last decade or so, you definitely have seen in the chronic segment.

    Answer, satakarni makkapati

    When I say chronic segment, essentially, like immunology, rheumatoid arthritis, etc., you are seeing a major drop, a major erosion in the prices. From my Hospira days when we launched Infliximab, the price erosion that I see now is very high. But still in the oncology segment, not the supportive oncology segment, the oncology segment, I still see the price erosions not reflecting to the extent what you see in the chronic segment. But having said that, Europe has a distinct flavour now with the price erosions that you are seeing and any company, any biosimilar developer and manufacturer who wants to be serious in their European business needs to at least prepare them for an overall 50% margin from the entire European market. There will be some countries that will give you 70-80%. There will be some countries that will give you 10-15%. As long as you keep your COGS in a manner that you have an overall margin of around 50%, you are good, which also means that you need to have a good and strong commercial positioning in Europe, across Europe, to make that happen.

  18. Question

    Shyam Srinivasan: Yeah, thank you. Thank you, Dr. Satakarni. My second question is… 14 Aurobindo Pharma Limited 05 August 2025 V. Muralidharan: Dr. Satakarni, maybe I can contribute here in addition to the eloquent reply what you gave.

    Answer, v muralidharan

    For example, countries like France, the generic substitutability trend is increasing, where it was hardly one or two products earlier, now, as many as nine products are in the list of generic substitutability and similar trend is to be expected in certain other countries as well, meaning there will be a higher volume uptake as we launch some of our products. So this is a positive trend for us, which we would like to encash on.

  19. Question

    Shyam Srinivasan: Helpful! Thank you. Just my last two questions. I will keep it very brief. First one, our experiences of this Lannett with the FTC vis-à-vis the Sandoz acquisition that did not go through, Subbu sir or Swami sir, anything, what gives you confidence that we can get through this FTC bar this time around versus that failed episode? And second question is, just a data point on the opening remarks. You said, 12% growth excluding gRevlimid. Is it US? Is it overall company? With the numbers you have shared, I am not able to come up with that number. So if you could help us. Thank you.

    Answer, swami iyer

    Swami Iyer: Yeah. First, I will take the question on FTC, Subbu. So on the FTC, we do not have any of the critical products that we think will have a conflict where we would be reluctant to look at it or we do not expect that many products where we would have this issue. We think it will be a smaller list based on our understanding, based on the advice that we have received and we think we should not have a problem with that kind of smaller list. What we are focused on, are some of the products where we think it will go through without any much difficulty. Obviously, it is a decision of FTC, but that is what gives us the confidence that the main product should be intact. So we have a little more flexibility in this.

  20. Question

    Shyam Srinivasan: Okay, sir. And US would be what? Sorry.

    Answer, s subramanian

    S. Subramanian: US, we are not given any specific number directly. We never used to give, but this is the overall Aurobindo as a whole on consol basis.

  21. Question

    Srikanth: Hi, good morning. Thanks for the opportunity. I have three questions. First question is on our annual guidance.

    Answer, s subramanian

    S. Subramanian: PEN-G unit currently, we are doing around 50 to 60%. We are trying to improve the yields. That is our primary objective to cut down the losses so that better yield will cut down the losses. And once we stabilize that in the next two months, we will scale it up. Srikanth: Okay. And now that you are restricting, so just one more question. So on the controlled substance business, we have seen some struggle by some of the Indian companies.

  22. Question

    Kunal Dhamesha: And on the 15% EBITDA margin that you suggested in the presentation for the Lannett acquisition, so is it for a particular year or do you plan to take it to 15%? How should we think about it?

    Answer, swami iyer

    Swami Iyer: Well, this is the current run rate. I mean, at this point of time, if I take the TTM trailing 12 months, if I take any period, we are somewhere around that and I believe that's a very conservative estimate. We think that in the future, we will be able to get a margin of 15% or more.

Questions about this call

When was the Aurobindo Pharma Q1 FY26 earnings call transcript filed?
Aurobindo Pharma filed the transcript with the exchange on 8 Aug 2025. This page is built from that transcript.
What does this page list?
49 statements from the transcript across 9 topics, 31 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 32 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Aurobindo Pharma Q1 FY26 concall: Aurobindo Pharma is confident of achieving its internal target margin of 20%-21% range in FY26 · DalalOS